Amgen (AMGN)
(Delayed Data from NSDQ)
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More
by Kinjel Shah
Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.
Pfizer (PFE) Beats on Q3 Earnings, Ups COVID Jab Sales View
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q3 earnings and sales. It ups its sales and earnings view despite a decline in COVID-19 vaccine sales in Q3. Stock up in pre-market trading
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Gilead Sciences Stock Climb After Q3 Earnings?
by Shaun Pruitt
Big Pharma will close out this week's earnings reports, with Gilead Sciences (GILD) set to give its Q3 results on October 27. With GILD edging towards its 52-week highs, investors will want to see if earnings can support a continued rally in its stock.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $251.94, marking a +1.81% move from the previous day.
Amgen (AMGN) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $247.45, marking a -0.3% move from the previous day.
Do Options Traders Know Something About Amgen (AMGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.
Amgen (AMGN) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $251.34, moving -0.13% from the previous trading session.
Strength Seen in Amgen (AMGN): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Amgen (AMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Amgen (AMGN) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Amgen (AMGN) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Stock Market News for Oct 12, 2022
by Zacks Equity Research
Wall Street closed mixed on Tuesday after a choppy session.
The Zacks Analyst Blog Highlights Chevron, Amgen, HSBC, CVS Health and S&P Global
by Zacks Equity Research
Chevron, Amgen, HSBC, CVS Health and S&P Global are included in this Analyst Blog.
Top Research Reports for Chevron, Amgen & HSBC
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and HSBC Holdings plc (HSBC).
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $232.15 in the latest trading session, marking a +1.36% move from the prior day.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $233.02 in the latest trading session, marking a +1.12% move from the prior day.
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
by Zacks Equity Research
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
by Zacks Equity Research
Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $225.99, marking a -0.39% move from the previous day.